
Opinion: The Biden administration needs to look beyond ICER for evaluating drug therapies
As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will get access to them remain thorny issues. During his campaign for president, Joe Biden …
Read More